Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

iBio and AzarGen go to next stage
October 2019
SHARING OPTIONS:

NEW YORK—In mid-September, iBio Inc. announced that it had entered into the initial statement of work under its memorandum of understanding (MOU) with AzarGen Biotechnologies (Pty.) Ltd. Following iBio’s successful use of its technologies and manufacturing capabilities to advance the development of AzarGen’s surfactant protein therapeutic through an initial assessment of production feasibility, in May 2017, the two companies expanded their collaboration by initiating the development of a plant-made rituximab for the South African market under the MOU.
 
“After demonstrating the success of our platform through our opening project with AzarGen, we are now advancing to the next stage of the two companies’ collaboration,” commented Robert B. Kay, iBio’s chairman and CEO. “We look forward to helping AzarGen develop a plant-based, biosimilar rituximab product for the South African market.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.